Kristen Doyle was approved by the governing body of the Cancer Prevention and Research Institute of Texas as the agency’s new CEO beginning July 1. Doyle, currently deputy executive officer and general counsel, will succeed Wayne Roberts who will step down on June 30 after 12 years as chief executive.
The governing body of the Cancer Prevention and Research Institute of Texas approved $51.8 million in grants to advance the state’s fight against cancer. The grants are a mix of academic research recruitment grants and product development research projects.
The Lymphoma Research Foundation has awarded 28 new research grants in 2024, amounting to $3.5 million to cancer researchers who will advance understanding of lymphoma and lay the foundation for improved patient care.
The International Agency for Research on Cancer welcomed the Kingdom of Saudi Arabia as a new participating state, underscoring the commitment to advancing cancer research and prevention in the country.
Researchers at UT Southwestern Medical Center have developed a novel artificial intelligence model to improve the detection of breast cancer metastasis, which could reduce the need for needle or surgical biopsies.
Orca Bio will present new data at the 2024 American Society of Clinical Oncology Annual Meeting in Chicago.Â
A new treatment approach using an older drug may enable more patients with high-risk blood cancers to receive transplanted stem cells from unrelated, partially matched donors, according to a study conducted by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and colleagues.
The Menarini Group and Stemline Therapeutics Inc., a wholly-owned subsidiary of the Menarini Group, will present updated results from phase Ib/II ELECTRA and ELEVATE clinical studies evaluating elacestrant (Orserdu) in combination with other treatments at the 2024 American Society of Clinical Oncology on June 2.Â
Updated clinical data from a phase Ib combination cohort evaluating vepdegestrant, an investigational oral proteolysis targeting chimera estrogen receptor degrader, in combination with palbociclib (Ibrance) are consistent with data presented at the San Antonio Breast Cancer Symposium in December 2023.
The National Comprehensive Cancer Network has published NCCN Guidelines for Patients: Small Bowel Adenocarcinoma.
